Tickerover
Sign inStart free→
Healthcare

ZTS Stock Analysis

Zoetis Inc. · current price $77.36 (+3.11% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
57
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
90
High quality
profitability & balance sheet
Valuation
35
Getting pricey
is the price fair?
Sentiment
40
Mixed views
analyst & crowd mood
Risk
49
Above-avg risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
RSI zoneRSI zone: 1001001-month momentum1-month momentum: 5050Trend strengthTrend strength: 6565Earnings accelerationEarnings acceleration: 100100FundamentalsFundamentals: 7676News sentimentNews sentiment: 9595Near 52w highNear 52w high: 7575
Margin profileWhat survives each step down the income statement.
GrossGross: 71.7%71.7%OperatingOperating: 40.7%40.7%NetNet: 27.7%27.7%Free cash flowFree cash flow: 24.3%24.3%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +95.0% vs estimate+95%2026-062026-03: -5.3% vs estimate-5%2026-032025-12: +5.5% vs estimate+5%2025-122025-09: +4.8% vs estimate+5%2025-09
👁

Hype Check

Reading ZTS’s price and volume history…

✓

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading ZTS’s filings…

📣

Latest earnings

LAST EARNINGS Zoetis Inc. (ZTS)

Latest earnings

EPS
$1.70 vs $1.62 est · +4.8% vs estimate BEAT
Revenue
$2.47B · +2.8% YoY
Stock reaction (1M)
+1.7%
Beat streak
3 of last 4 quarters
💰

Valuation

P/E
12.6×
Forward P/E
11.8×
PEG
6.72
Price / Sales
3.4×
EV / EBITDA
9.7×
Analyst target
$96.00
Target range
$80.00 – $155.00
Implied upside
+24.1%
🩺

Financial health

Gross margin
71.7%
Operating margin
40.7%
Net margin
27.7%
FCF margin
24.3%
Return on equity
64.9%
Debt / equity
2.94
Revenue growth YoY
-0.2%
EPS growth YoY
+1.2%
📈

Technicals

$71.0052-week range$155.38
RSI (14)
53
50-day MA
$75.67
200-day MA
$104.14
ATR (14)
2.52
Beta
0.73
1-month return
+1.7%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$1.70$1.62+4.8%Beat
2025-12-31$1.48$1.40+5.5%Beat
2026-03-31$1.53$1.62-5.3%Miss
2026-06-30$1.87$1.85+0.9%Beat
Beat 3 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.05%
Dividend yield
2.74%
Beta
0.73
📰

Latest news on ZTS

🔗

Similar stocks in Healthcare

DXCMDexCom, Inc.CONConcentra Group Holdings Parent, ISHCSotera Health CompanyACADACADIA Pharmaceuticals Inc.BLFSBioLife Solutions, Inc.AAgilent Technologies, Inc.

View all Healthcare stocks →

❓

Frequently asked

What is ZTS's Quant Score?

Zoetis Inc. (ZTS) currently has a TickerMover Quant Score of 58/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Zoetis Inc. (ZTS) a buy?

TickerMover does not give buy or sell recommendations. ZTS scores 58/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is ZTS's score updated?

ZTS's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Tickerover

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for ZTS →
TickerMover is a research tool, not financial advice. Quant Score is a composite signal — always do your own research before investing.
Last updated automatically every 5 minutes during US market hours.